RO4917838

DRUG13 trials

Sponsors

Hoffmann-La Roche

Conditions

Healthy VolunteerSchizophrenia

Phase 1

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

CompletedNCT01116830

Hoffmann-La RocheSchizophrenia

Start: 2010-11-30End: 2014-02-28Updated: 2016-11-02

A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838

CompletedNCT01356550

Hoffmann-La RocheHealthy Volunteer

Start: 2011-06-30End: 2011-10-31Updated: 2016-11-02

A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers

CompletedNCT01365403

Hoffmann-La RocheHealthy Volunteer

Start: 2011-04-30End: 2011-07-31Updated: 2016-11-02

A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers

CompletedNCT01433575

Hoffmann-La RocheHealthy Volunteer

Start: 2011-09-30End: 2011-11-30Updated: 2016-11-02

A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

CompletedNCT01438749

Hoffmann-La RocheHealthy Volunteer

Start: 2011-10-31End: 2012-05-31Updated: 2016-11-02

A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers

CompletedNCT01495104

Hoffmann-La RocheHealthy Volunteer

Start: 2011-10-31End: 2012-01-31Updated: 2016-11-02

A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838

CompletedNCT01510899

Hoffmann-La RocheHealthy Volunteer

Start: 2011-10-31End: 2012-03-31Updated: 2016-11-02

A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers

CompletedNCT01543529

Hoffmann-La RocheHealthy Volunteer

Start: 2012-02-28End: 2012-06-04Updated: 2017-05-10

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

CompletedNCT01613040

Hoffmann-La RocheHealthy Volunteer

Start: 2009-01-31End: 2009-07-31Updated: 2016-11-02

A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers

CompletedNCT01665976

Hoffmann-La RocheHealthy Volunteer

Start: 2012-08-31End: 2012-11-30Updated: 2016-11-02

Phase 2

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

CompletedNCT00616798

Hoffmann-La RocheSchizophrenia

Start: 2008-03-31End: 2010-02-28Updated: 2014-06-24

Phase 3

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

CompletedNCT01192867

Hoffmann-La RocheSchizophrenia

Start: 2010-12-11End: 2014-05-26Updated: 2017-06-26

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

CompletedNCT01235520

Hoffmann-La RocheSchizophrenia

Start: 2011-01-31End: 2014-07-31Updated: 2015-06-02

Related Papers

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.

2017-03-1898 citations

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.

2016-11-0276 citations

Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia

JAMA Psychiatry2014-04-02227 citations

Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.

2012-09-1210 citations